Company Overview and News
Oshkosh Defense, LLC, an Oshkosh Corporation (NYSE: OSK) company, will debut the Family of Medium Tactical Vehicles (FMTV) A2 variant, as well as showcase multiple Joint Light Tactical Vehicles (JLTV) at the 2018 AUSA Conference. The vehicles will be on display at the Walter E. Washington Convention Center in Washington, D.C. from Monday, October 8th through Wednesday, October 10th, 2018.
Over the span of two weeks, General Motors Company (GM - Free Report) has again been caught into a recall mess. Per Reuters, this U.S. auto giant announced that its China joint venture, Shanghai GM, will recall over 3.3 million vehicles in China from Oct 20. Per the State Administration for Market Regulation, the market regulator in China, flaw in the suspension system led to this recall and vehicles that would be recalled include Buick, Chevrolet and Cadillac produced between 2013 and 2018.
FOXF OSK GM ALSN
2018-10-02 zacks - 1
Chicago, IL – October 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Meritor, Inc. (MTOR - Free Report) , Allison Transmission Holdings, Inc. (ALSN - Free Report) , Commercial Vehicle Group, Inc. , Cummins Inc.
CVGI STZ.B COST WTW ALSN STZ SFIX CMI CMQMY OSK KWR LULU MTOR FSLR
During the last few hours of Sep 30, the United States and Canada reached a landmark deal, which replaces the North American Free Trade Agreement (NAFTA). The new agreement followed a weekend of hectic talks aimed at keeping alive a 25-year old agreement between the two countries and Mexico.
CVGI CMQMY OSK MTOR ALSN FSLR CMI
CarMax Inc. (KMX - Free Report) has posted earnings per share of $1.24 in the second quarter of fiscal 2019 (ended Aug 31, 2018), up 26.5% from 98 cents in the year-ago quarter. Moreover, earnings surpassed the Zacks Consensus Estimate of $1.22. Net sales and operating revenues in the reported quarter increased 8.6% year over year to $4.77 billion. Further, the figure beat the Zacks Consensus Estimate of $4.
FOXF OSK KMX ALSN CAXPF
Oshkosh Defense, LLC, an Oshkosh Corporation (NYSE: OSK) company, will showcase three variants of the Joint Light Tactical Vehicle (JLTV) at Modern Day Marine Expo 2018. The vehicles will be on display at Quantico Marine Corps Base in Quantico, Virginia from Tuesday, September 25th through Thursday, September 27th.
Per AP, Nissan Motor Company (NSANY - Free Report) has recalled nearly 240,000 vehicles, globally. The recalled vehicles include cars and sport utility vehicles (SUVs) that have chances of catching fire. Per Nissan, the anti-lock brake pump — consisting of brake fluid — can leak onto circuit board, which may result in electrical short and fire. The brake fluid leakage is due to defective seals in the anti-lock brake pump.
Magna International Inc. (MGA - Free Report) announced that its Powertrain unit inked a deal to divest its global Fluid Pressure & Controls (“FP&C”). For this divestiture, the company signed an agreement with Hanon Systems, a global supplier of thermal and energy management systems based in South Korea, for $1.23 billion. With this divestiture, the Powertrain division of Magna, which is the leading manufacturer and supplier of automotive components, is going to focus more on becoming full-system supplier of transmission and other driveline-related systems.
FOXF KBH OSK MGA MG ALSN
Have you been paying attention to shares of Allison Transmission Holdings (ALSN - Free Report) ? Shares have been on the move with the stock up 9.6% over the past month. The stock hit a new 52-week high of $53.55 in the previous session. Allison Transmission Holdings has gained 24.1% since the start of the year compared to the -5.8% move for the Zacks Auto-Tires-Trucks sector and the -1.7% return for the Zacks Automotive - Original Equipment industry.
OSK MTOR ALSN AAP THRM
Thor Industries, Inc. (THO - Free Report) reported fourth-quarter fiscal 2018 (ended Jul 31, 2018) adjusted earnings of $1.67 per share, missing the Zacks Consensus Estimate of $1.93. Moreover, adjusted earnings decreased roughly 26% from the year-ago figure of $2.26. Net income declined to $88.2 million from $119.5 million in the prior-year quarter. For fiscal 2018, adjusted earnings per share increased year over year from $7.
OSK THO PCAR
Genuine Parts Company (GPC - Free Report) announced that it is acquiring companies for its two groups. One of the acquisitions is for its Industrial Parts Group that operates under the name Motion Industries, while the other is for its U.S. Automotive Parts Group. Genuine Parts’ Motions Industries has signed an agreement to acquire Sunrise, FL-based Hydraulic Supply Company (“HSC”). Established in 1947, HSC is a leading distributor of hydraulic, pneumatic, and industrial components and systems.
Copart, Inc. (CPRT - Free Report) reported adjusted earnings per share of 42 cents in fourth-quarter fiscal 2018 (ended Jul 31, 2018), missing the Zacks Consensus Estimate of 47 cents. The bottom line improved 20% from 35 cents recorded in the year-ago quarter. Net income was $109.7 million, reflecting a surge of 56% or $39.4 million from fourth-quarter fiscal 2017. Copart’s revenues rose 18.7% to $449.
FOXF OSK CPRT ALSN
Investors with an interest in Automotive - Original Equipment stocks have likely encountered both Oshkosh (OSK - Free Report) and Ferrari (RACE - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
In a notable development, Thor Industries, Inc. (THO - Free Report) has agreed to buy Germany’s Erwin Hymer Group SE (“EHG”) for €2.1 billion ($2.5 billion), marking its biggest acquisition. This cash and stock deal is likely to open up chances before the Elkhart, IN-based recreational vehicle (“RV”) manufacturer, Thor to stamp its position in the growing European RV market. On the other hand, Hymer family finds a ‘new owner partner’ in Thor Industries for Erwin Hymer Group to effectively go on with its long-term growth and internationalization strategy.
FOXF OSK THO ALSN
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to OSK / Oshkosh Corporation on message board site Silicon Investor.
as of ET